This article traces the shifting fortunes of for-profit psychedelic medicine through two phases: a boom from 2016 to late 2021, followed by a bust that continued through late 2024. It argues that the forces driving this cycle are best understood through the concept of capitalization, which links...

Background In their interesting systematic review, Gallehzan et al. quoted our article Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing-remitting multiple sclerosis (RRMS) in Italy. While we are grateful to Gallehzan et al. for their interest in the...

Simulation modelling has widely been applied in healthcare supply chain management, focusing on blood and vaccine supply chains with less attention on the medicine supply chains. This study presents a systematic review of studies applying simulation methods, namely agent-based modelling,...

Finding effective treatment for patients with rare diseases can be very difficult. Since the EU orphan regulations entered into force in 2000, it has played a central role in facilitating the development and authorisation of medicines for rare diseases.

In 2024, EMA recommended 114 medicines for marketing authorisation. Of these, 46 had a new active substance which had never been authorised in the European Union (EU) before. Among these are a number of medicines that stand out due to their contribution to address public health needs or the...

EMA has published an overview of its key recommendations of 2024 regarding the authorisation and safety monitoring of veterinary medicines. In 2024, EMA recommended 25 veterinary medicines for marketing authorisation - the highest ever number of recommendations in a year. Of these, two had a new...

In 2024, EMA recommended 114 medicines for marketing authorisation. Of these, 46 had a new active substance which had never been authorised in the European Union (EU) before. Among these are a number of medicines that stand out due to their contribution to address public health needs or the...

EMA has published an overview of its key recommendations of 2024 regarding the authorisation and safety monitoring of veterinary medicines. In 2024, EMA recommended 25 veterinary medicines for marketing authorisation - the highest ever number of recommendations in a year. Of these, two had a new...

In the last quarter of 2020, the European medicines agencies network - comprising national competent authorities (NCAs) and the European Medicines Agency (EMA) - published its five-year strategy covering the period from 2021 to 2025. The strategy (EMANS 2025) has now undergone an update to cover...

In the last quarter of 2020, the European medicines agencies network - comprising national competent authorities (NCAs) and the European Medicines Agency (EMA) - published its five-year strategy covering the period from 2021 to 2025. The strategy (EMANS 2025) has now undergone an update to cover...

EU Drug Market: MDMA describes the European MDMA market from production to trafficking, distribution and use. It details the materials, processes and players involved at different stages and levels of the market. The module takes a threat assessment approach, identifying key issues and defining...

This protocol presents an updated common methodology for estimating COVID-19 vaccine effectiveness (VE) using established health data registries in participating European Union (EU) and European Economic Area (EEA) Member States. This work is performed within the Vaccine Effectiveness, Burden...

Sharing used injection equipment is one of the main ways in which drug users run the risk of infection (e.g., with HIV, or hepatitis B and C). This has led to the introduction of harm reduction (HR) strategies, such as needle exchange programmes (NEPs). Injection use is considered to be less...

This study focuses on the precise forecasting of stock price movement to determine returns, diversify risk, and demystify existing opportunities. It also aims to gauge the difference in terms of the stock volatility of various pharma companies before and during the pandemic era. The prediction...

Welcome to the 2024 EMA annual report, which highlights milestones and achievements of the past year, and our regulatory network's commitment to bringing value to public and animal health in the European Union (EU).

This page provides an overview of key issues related to the provision of harm reduction equipment for high-risk drug use, including service delivery, guidance and evidence, and considerations for implementation. It also considers implications for policy and practice.

Background Evidence on the cost effectiveness of deprescribing in multimorbidity is limited. Objective To investigate the cost effectiveness of a general practitioner (GP) delivered, individualised medication review to reduce polypharmacy and potentially inappropriate prescribing in older...

Objectives The aim of this study is to analyse the trends in technology appraisals for non-small cell lung cancer (NSCLC) treatments performed by the National Institute for Health and Care Excellence (NICE) over the last ten years. Methods A systematic search was conducted for single technology...

The 340B Drug Pricing Program was instituted to bolster the health care safety net without relying on taxpayer money. It allows participating health care facilities - most of which are hospitals - to purchase drugs filled at in-house or contracted external pharmacies at discounts from...

Community pharmacies deliver high-quality health care and are responsible for medication safety. The goal of the government is to ensure nationwide, accessible, and affordable medical health-care services provided by pharmacies. Therefore, the per capita density of community pharmacies matters....

Cervical cancer, primarily caused by persistent Human Papillomavirus (HPV) infection, remains one of the leading causes of cancer-related deaths among women in developing countries. Although HPV vaccines are widely available in these regions, vaccine uptake remains persistently low. To address...

This paper examines the effects of data privacy regulation on R&D investment in the pharmaceutical and biotechnology sectors. In these industries, access to personal health data is essential for innovation, particularly in clinical research. Leveraging a firm-level panel of the world's top R&D...

This report outlines the threat of pharmaceutical crime in the EU and beyond, as assessed by Europol. It aims to raise awareness of the ways criminal networks exploit consumers and industry in generating illegal revenue through producing and selling counterfeit medicines.

Patients in rural areas have higher rates of opioid use and overdose than those in urban areas that are linked to the greater prevalence and amounts of opioids prescribed. We merge individual claims data with county-level supply and demand factors to examine this relationship between...